Trial Profile
The case control study of Option B+ (Tenofovir/Lamivudine/Efavirenz (TLE) combined) as one of the strategies to eliminate mother to child HIV transmission (eMTCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Mar 2018
Price :
$35
*
At a glance
- Drugs Efavirenz/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 26 Mar 2018 New trial record
- 04 Mar 2018 Results of vertical transmission among pregnant/breastfeeding women on TLE were presented at the 18th International Congress on Infectious Diseases